Glucose Tolerance & Insulin Response in Patients with Hypertension
Glucose tolerance & insulin response in patients with hypertension
Keywords:
Glucose tolerance, Hypertension, Insulin, Insulin resistanceAbstract
Background: Insulin resistance leads to impaired glucose tolerance, dyslipidemia, and other adverse cardiovascular effects. Euglycemic insulin clamp have shown that essential hypertension per se is a state of insulin resistance and has been associated with an increased incidence of diabetes Aims: To ascertain the prevalence of several degrees of glucose abnormalities in patients with hypertension and to examine the insulin secretory response to oral glucose load. Study design, Material and Method: This cross-sectional analytical study included 325 hypertensive patients (with or without diabetes)and 100 control subjects. An oral glucose tolerance test (OGTT) following WHO guidelines was performed in all subjects, with measurement of insulin at baseline and every 30 minutes after the glucose load. Results: Abnormal glucose metabolism was observed in 70.77% of patients (95% confidence interval [CI], 65.87% - 74.21%). Of the 325 patients, 29.23% patients showed normal glucose metabolism. Impaired glucose tolerance (IGT) and Impaired fasting glycemia (IFG) were diagnosed in 30.46% and 16.61% patients respectively .Total diabetic population in the hypertensive patients were 23.69% (silent previously undiagnosed diabetes mellitus was diagnosed in 9.53% of patients while 14.15%reported a previous diagnosis of diabetes mellitus).Decreasing glucose tolerance was associated with insulin resistance. From normal glucose tolerance condition through IGT, IFG to diabetic, the HOMA IR progressively increased. Results of standard OGTT and corresponding insulin response after 0, 30, 60 and 120 minutes were significantly higher in patients compared with control subjects. LVMI and severity of glucose intolerance were significantly related. Male gender, higher levels of insulin (fasting insulin/HOMA IR) and greater adiposity (BMI) were all strongly associated with the severity of glucose abnormalities. Prevalence of metabolic syndrome increased progressively with severity of glucose abnormality. Conclusions: More than two-third of the hypertensive patients exhibited different glucose abnormalities and exaggerated insulin response to glucose load (hyperinsulinemia) along with cluster of other cardiovascular risk factors, whose prevalence increases with severity of glucose intolerance.
References
2. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetesmellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12.
3. Gallagher EJ, Leroith D, Karnieli E. The metabolic syndrome-from insulin resistance to obesity and diabetes.Med Clin North Am 2011;95(5):855-73.
4. Okin PM, Devereux RB, Harris KE, Jern S, Kieldsen SE, Lindholm LH, Dahlof B. In treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new onset diabetes mellitus in hypertensive patients: the lsartan intervention for Endpoint Reduction in Hypertension(LIFE)Study.
5. Felicio JS, Ferreira SR, Plavnik FL, Moises V, Kohlmann O, Ribeiro AB, Zanella MT. Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens 2000;13:1149-1154.
6. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
7. Devereux RB, Reichek W. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1997;55:613-618.
8. Verdecchia P, Schillaci G, Borgioni C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
9. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28:1039-57.
10. American Diabetes Association: Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33:S62-S69.
11. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61.
12. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
13. Fossati P,Prencipe L. Serum triglycerides determined colorimetrically with an enzyme
that produces hydrogen peroxide. Clin Chem 1982;28:2077-80.
14. Burstein M, Morfin R. Precipitation of alpha lipoproteins in serum by sodium phosphotungstate in the presence of magnesium chloride. Life Sci 1969;8:345-8.
15. Trivelli LA, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. N Engl J Med 1971;284:353-7.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Sobey WJ, Beer SF, Carrington CA. Sensitive and specific two site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 1989;20:1183-1197.
18. Hasslacher C. Clinical significance of microalbuminuria and evaluation of the Micral-Test. Clin Biochem 1993;26:283-7.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor GA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19.
20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
21. Nishanan LK, Uusitupa MI, Pyörälä K. The relationship of hyperinsulinemia to the development of hypertension in type 2 diabetic patients and in nondiabetic participants. J Hum Hypertens 1991;5:155–59.
22. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta S, Landsberg L. Effect of insulin and glucoseinfusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219–25.
23. DeFronzo RA, Goldberg M, Agus ZA. The effects of glucose and insulin on renal electrolyte transport.J Clin Invest 58:83–90.
24. Moore RD. Effects of insulin upon ion transport. Biochim Biophys Acta 1983;737:1–49.25. Stout RW, Bierman EL, Ross R. Effects of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975;36:319–27.
26. Aviv A, Gardner J. Racial differences in ion regulation and their possible links to hypertension in blacks. Hypertension 1989;14:584–89.
27. Creager MA, Liang C-S, Coffman JD. β-Adrenergic—mediated vasodilator response to insulin in thehuman forearm. J Pharmacol Exp Ther 1985;235:709–14.
28. Scott AR, Bennett T, MacDonald IA. Effects of hyperinsulinemia on the cardiovascular responses to graded hypovolemia in normal and diabetic participants. Clin Sci 1988;75:85–92.
29. V Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletalmuscle blood flow in obese men: a novel mechanism for insulin resistance. J Clin Invest 1990;85:1844–52.
30. Alexander WD, Oake RJ. The effect of insulin on vascular reactivity to norepinephrine. Diabetes 1977;26:611–14.
31. M Heise T, Magnusson K, Heinemann L, Sawicki PT. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension 1998;32:243–48.
32. Genev NM, Lau IT, Willey KA, Molyneaux LM, Xu ZR, Zilkens RR, Wyndham RN, Yue DK. Does insulin therapy have a hypertensive effect in type 2 diabetes. J Cardiovascular Pharmacol 1998;32:39–41.
33. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus:current concepts. Am J Med 2004;116(suppl 5A):11S-22S.
34. De Simone G, Palmieri V, Bell JN. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002;20:323-31.
35. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum on non diabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998;128:524-33.
36. Norhammar A, Tenerz A, Nilsson G. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of
diabetes mellitus: a prospective study. Lancet 2002;359:2140-44.
37. Mastsude A, Emoto S , Yoshiki N. Homesostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999;22:818-22.
38. Muhammad A. Abdul-Ghani, Valeriya Lyssenko, Tiinamaija Tuomi, Ralph A. Defronzo, Leif Groop. Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes. Diabetes Care 2009;32(2):281-86.
